Prostatype Genomics AB, a Sweden-based company that manufactures, markets and sells the prognostic gene test, Prostatype, announced on Friday that it has named Professor Gerald Andriole as its new global chief medical officer.

Professor Andriole has over 35 years of experience in urology. He has served as professor in the Department of Urology and director of the Brady Urological Institute in the National Capital Region of Johns Hopkins University. He has worked as the Robert K. Royce distinguished professor and chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri. He has worked as the Chairman of the Prostate Committee of the National Cancer Institute's prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial; chairman of the Prostate Committee for the Society of Urologic Oncology Clinical Trials Consortium; and chairman of the Steering Committee of the REDUCE International Prostate Cancer Prevention Trial.

Fredrik Persson Prostatype Genomics CEO said, 'We are honoured that professor Andriole has decided to join Prostatype Genomics. His strong track record as an investigator, his reputation as an internationally recognised key opinion leader in Urology and significant focus on men with prostate cancer provides us with the expertise to bring a benchmark test like Prostatype to physicians and patients. His research and clinical experience, much of which focuses on genomic testing, allows him to continue to positively impact the quality of care and outcomes for patients diagnosed with prostate cancer. Professor Andriole's background will provide significant guidance to Prostatype Genomics in the US as well as globally.'